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Abstract Death-associated protein kinase 1 (DAPK1), a
Ca2+/calmodulin (CaM)-dependent serine/threonine protein
kinase, plays important roles in diverse apoptosis pathways
not only in tumor suppression but also in neuronal cell death.
The requirement of DAPK1 catalytic activity for its proposed
cell functions and the elevation of catalytic activity of DAPK1
in injured neurons in models of neurological diseases, such as
ischemia and epilepsy, validate that DAPK1 can be taken as a
potential therapeutic target in these diseases. Recent studies
show that DAPK1-NR2B, DAPK1-DANGER, DAPK1-p53,
and DAPK1-Tau are currently known pathways in stroke-
induced cell death, and blocking these cascades in an acute
treatment effectively reduces neuronal loss. In this review, we
focus on the role of DAPK1 in neuronal cell death after stroke.
We hope to provide exhaustive summaries of relevant studies
on DAPK1 signals involved in stroke damage. Therefore,
disrupting DAPK1-relevant cell death pathway could be con-
sidered as a promising therapeutic approach in stroke.
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Introduction
Stroke, a major cause of morbidity and mortality, affects mil-
lions of lives worldwide every year [1]. It is either due to
cerebral ischemia or hemorrhage and is followed with a series
of complex biochemical incidents that leads to the total break-
down of cellular integrity and eventually cell death.
Accumulative evidence suggests that ischemic stroke-induced
neuronal cell death is likely due to excitotoxicity for an exces-
sive stimulation of glutamate receptors [2–4] resulting in Ca2+
overloading, oxidative radical stress involved in reactive oxy-
gen species (ROS)/reactive nitrogen species (RNS) produc-
tion [2, 5–7], and suicidal events such as apoptosis and necro-
sis [5, 6, 8, 9]. Blocking the glutamate receptors after ischemic
insults has been shown to both be effective [1] and have severe
side effects in stroke therapy [10]. Therefore, glutamate recep-
tors are not desired targets in preventing ischemic neuronal
death. Spectacular failures in drug development programs
and clinical trials for neuroprotective agents have led to the
withdrawal of funding aimed at developing new drugs for
stroke [1]. The direct and effective treatments for stroke re-
main lacking other than reopening an occluded artery with
thrombolytic drugs, which makes the identification of new
therapeutic targets a matter of great importance.
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Death-associated protein kinase 1(DAPK1), identified in a
screen for genes that influence γ-interferon (IFN)-induced cell
death in HeLa cells [11], is a 160-kDa Ca2+/calmodulin-de-
pendent serine/threonine protein kinase [12] whose phosphor-
ylation activity is known to be responsible for certain forms of
apoptotic cell death, including Fas, tumor necrosis factor
(TNF)-α [13], ceramide [14], caspase [15], and p53-
mediated apoptosis [16], as well as in the disruption of matrix
survival signals and suppression of integrin-mediated cell ad-
hesion [17]. In addition, DAPK1, which is abundantly
expressed in the brain, has been linked to neurological dis-
eases associatedwith neuronal injury andmay serve as a target
for therapeutic intervention in the treatment of stroke, epilep-
sy, and Alzheimer’s disease. DAPK1 is of particular interest in
stroke to us because of a quantitative proteomic analysis of the
death-signaling proteins that are enrolled to the cytoplasmic
tail of the N-methyl-D-aspartate receptor (NMDAR) during
cerebral ischemia revealing DAPK1 as the most prevalent
protein [18]. Over the past decades, several groups have made
efforts to decipher DAPK1’s cellular function in stroke, focus-
ing on its biochemical properties, regulation, and especially
the target substrates in ischemic injuries. It has become appar-
ent that DAPK1 has multiple roles and is linked to several cell
death-related signaling pathways in ischemia. The purposes of
this review are to provide a comprehensive overview of the
recent literatures on DAPK1 signals in ischemic stroke and to
help us better understand the molecular mechanisms of neu-
ronal cell death during stroke injuries.
A General Introduction of DAPK1
DAPK1 has a unique multidomain structure containing an N-
terminal kinase domain, followed by a calmodulin (CaM) reg-
ulatory segment, eight ankyrin repeats, a cytoskeleton binding
region, two P-loop motifs, and a C-terminal death domain as
well as a stretch of amino acids that are rich in serines and
threonines [19] (Fig. 1). DAPK1 belongs to a family of related
death protein kinases, which consists of other two closely
related homologs: ZIP kinase (ZIPK, also known as DAP-
like kinase (Dlk) or DAPK3) [20, 21] and DAPK-related pro-
tein 1 (DRP-1, also known as DAPK2) [22, 23], whose human
genes share 83 and 80 % of the identity of amino acids, re-
spectively, with DAPK1’s kinase domain. The death-
promoting effects of DAPK1 mostly depend on its catalytic
activity which is under tight control, to ensure on one hand its
silence under normal growth conditions, and to allow, on the
other hand, rapid activation in response to the appropriate
apoptotic signal.
The identification of myosin light chain (MLC) as a sub-
strate of DAPK1 facilitated the performance of in vitro
DAPK1 kinase assays which enables the analysis of different
aspects of its catalytic activity and of its mode of regulation
[24]. DAPK1 is regulated by a number of mechanisms. Firstly,
the CaM-regulatory segment, which acts as a pseudosubstrate
to the cleft of kinase domain, possesses an auto-inhibitory
effect on the catalytic activity and can be relieved by binding
to Ca2+-activated CaM [25] and therefore activates DAPK1.
Second, DAPK1 is negatively regulated by autophosphoryla-
tion on serine 308 in the Ca2+/CaM regulatory domain at the
basal level. Dephosphorylation relieves autoinhibition, en-
hances the interaction between CaM and the DAPK1 CaM-
regulation segment, and stimulates its proapoptotic activities
[25]. Consistently, the mere deletion of this segment from
DAPK (ΔCaM) or the mutation of Ser308 to alanine
(S308A) generates a constitutively active kinase.
The catalytic activity of DAPK1 is controlled by distinct
mechanisms. First, DAPK1 loses catalytic activity upon mu-
tation of Lys42 to Ala (K42A) [19], one of the amino acids
critical to the binding with ATP [26]. Second, extracellular-
regulated protein kinase1/2 (ERK1/2) binds a docking site
within DAPK1’s death domain and phosphorylates DAPK1
Ser735 within the cytoskeletal binding region both in vitro
and in vivo, stimulating DAPK1 catalytic activity [27].
Third, the p90 ribosomal S6 kinase (RSK), a downstream
effector of ERK, inhibits exogenous DAPK1 cellular activity
by phosphorylation of Ser289 within the CaM-autoregulatory/
binding segment [28]. Last but not least, DANGER, denoted
by Damian B et al., inhibits DAPK1 activity towardMLC in a
concentration-dependent manner, without influencing cal-
modulin’s binding to DAPK1 [29]. Then, how is DAPK1
activated during ischemic stroke? It is known that cerebral
ischemia induces overexcitation of the NMDA receptor, caus-
ing excessive Ca2+ flow into the cytoplasm and activates not
only CaMbut also the calcineurin phosphatase (CaN) [30] and
dephosphorylates DAPK1 in Ser308. Then, DAPK1 com-
bines with CaM and becomes activated.
DAPK1 and its Kinase Activity in Ischemic Neuronal
Death
In the developing and adult central nervous system, DAPK1
mRNA is widely expressed in proliferative regions within the
Fig. 1 Schematic diagram of human-derived DAPK1 protein structure. Shown are the known functional domains of human DAPK1. See text for details
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cerebral cortex and hippocampus [31, 32]. In addition,
DAPK1 is critically involved in the processes of both neuronal
development and recovery from injury, as its activity is in-
creased in response to hypoxic ischemia [24, 33]. The tempo-
ral and spatial pattern of regulation suggests an important role
of DAPK1 in neuronal functions. The expression of DAPK1
mRNA is increased prior to selective cell death induced
by transient forebrain ischemia, indicating a close rela-
tionship between DAPK1 and neuronal cell death [32].
Moreover, a small molecule inhibitor of DAPK, alkylated
3-amino-6-phenylpyridazine, significantly attenuates
brain injury after ischemic stroke [34]. In addition, the
activation of DAPK1 has also been implicated in seizure-
induced neuronal death [35, 36].
The cell death-inducing activation of DAPK1 largely de-
pends on its intrinsic kinase activity [19]. For example, the
overexpression of intact DAPK1, but not of the catalytically
inactive kinase mutant in HeLa cells, induces apoptotic cell
death. It has been demonstrated that DAPK1 phosphorylates
diverse substrates via its kinase domain. These substrates in-
clude the MLC [19], beclin-1 [37, 38], zipper-interacting pro-
tein kinase (ZIPK) [39, 40], calmodulin-regulated protein ki-
nase kinase (CaMKK) [41], and syntaxin-1A [42]. The re-
quirement of DAPK catalytic activity for its proposed cell
functions and the validation of protein kinases as therapeutic
targets in human disease make the identification of substrates
of DAPK1 in ischemia extremely important.
DAPK1 and NR2B
During stroke, energy failure occurs and ionic gradients are
lost, then glutamate is released accompanied by impaired re-
uptake processes, and this redundant excitatory amino acid
binds to its postsynaptic receptors and also leaks out to the
extrasynaptic receptor and promotes excessive calcium entry
and calcium release, triggering neuronal death signaling. N-
methyl-D-aspartate receptors (NMDARs) are cation channels
that are gated by glutamate in the brain. Like a double-edged
sword, NMDARs play very important roles in both neuronal
health and neuronal death. It is known that NMDAR-induced
responses depend on the receptor location and subunit consti-
tution. For example, the activation of synaptic NMDARs,
mainly NR1 and NR2A, acting primarily through nuclear
Ca2+ signaling, leads to the build-up of a neuroprotective
Bshield^ [43], whereas stimulation of extrasynaptic
NMDARs (NR2B) promotes neuronal cell death [44].
A study by Tu et al. reported that DAPK1 is directly linked
to the NR2B subunit and initiates a specific cell death signal-
ing [18]. They identified that DAPK1 directly binds with the
carboxyl tail region consisting of amino acid 1292–1304
(NR2BCT) of the NR2B subunit. A constitutively active
DAPK1 phosphorylates the NR2B subunit at Ser-1303 and
in turn enhances the NR1/NR2B receptor channel
conductance. The administration of a peptide NR2BCT1292–
1304 to uncouple of the activated DAPK1 from the NMDA
receptor complex protects against brain damage in stroke
without affecting the physiological actions of the NMDA re-
ceptors (Fig. 2). Thus, targeting DAPK1-NMDA receptor in-
teraction can be considered as a practical strategy for stroke
therapy [45].
DAPK1 and p53
Tumor suppressor gene p53 is a transcriptional regulator and
controls the program of necrotic and apoptotic pathways of
cell death involved in the neurodegeneration progress includ-
ing ischemic stroke, epilepsy, and Alzheimer’s disease
through transcriptional-dependent and transcriptional-
independent mechanisms [46–48]. DAPK1 is considered a
kinase of human p53 at serine-20 (pS20), a residue corre-
sponding to mouse p53 at serine-23 (pS23, 19QETFSGL25)
[49]. It has been reported that DAPK1 might interact with p53
and mediate neuronal apoptosis in epilepsy [36]. Necrosis and
apoptosis are two distinct types of mechanisms that mediate
ischemic injury. Previous studies report that the expression of
an exogenous p53 gene is sufficient for the induction of neu-
ronal apoptosis [50–52]. However, the expression of exoge-
nous p53 in the p53−/− neurons alone in the absence of con-
stitutively active DAPK1 (cDAPK1) does not cause apopto-
sis, showing that pS23 is an essential substrate of cDAPK1.
Recently, Pei et al. found that activated DAPK1 phosphory-
lates p53 at serine-23 (pS23) via a direct binding of DAPK1
death domain (DAPK1DD) to the DNA-binding motif of p53
(p53DM), converging the signaling point of necrotic and ap-
optotic pathways in stroke [53]. They verified that the pS23
was located in both the mitochondria and the nucleus in the
cultured cortical neurons. In the nucleus, pS23 induces the
expression of proapoptotic genes, such as Bax and Puma,
whereas in the mitochondrial matrix, pS23 triggers necrosis
via interaction with cyclophilin D (CypD) in the cultured cor-
tical neurons of mice (Fig. 3). Using yeast two-hybrid analysis
and GST affinity binding assay, the authors confirmed that
DAPK1DD is bound to a p53 DNA-binding motif consisting
of amino acids 241–281 (p53DM241–281) [48]. The application
of a synthesized membrane-permeable p53DM241–281 peptide
(Tat-p53DM) that interrupts DAPK1-p53 interaction blocks
these dual pathways of pS23 actions in vitro and in vivo
[54]. Thus, the DAPK1-p53 interaction is a signaling point
of convergence of necrotic and apoptotic pathways and is a
desirable target for the treatment of ischemic insults.
DAPK1 and Tau
Tau, abundantly expressed in the nervous system, plays a cru-
cial role in neurodegenerative diseases such as Alzheimer’s
disease. There are 79 potential serine and threonine
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phosphorylation sites on the longest human Tau isoform.
Phosphorylation of these sites plays important roles in embry-
onic development, neurodegeneration, and ischemic stroke-
induced neuronal death [55, 56]. The interaction between
DAPK1 and Tau has been demonstrated in a few studies.
DAPK1 could regulate microtubule synthesis, neuronal differ-
entiation, and Tau toxicity by activating microtubules affinity
kinase1/2 (MARK1/2) [57] and regulate the Tau protein
Fig. 2 Illustration for DAPK1-
NR2B. DAPK1 is inactive in
physiological state. After cerebral
ischemic stroke, DAPK1 is
activated (cDAPK1,
constitutively active DAPK1) and
combines with the extrasynaptic
NMDARs, phosphorylating the
serine 1303 in the NR2B C-
terminal (CT) tail and mediating
cell death. Blocking DAPK1-
NMDARs interaction with an
NR2BCT-interfering peptide
resists ischemic stroke damage
Fig. 3 Illustration for DAPK1-
p53. The interaction of DAPK1–




binds to p53DM and
phosphorylates p53 at serine 23
(pS23), which on one hand
translocates into the nucleus and
activates the proapoptotic gene
expression and apoptosis. On the
other hand, the pS23 also enters
into the mitochondrial matrix and
interacts with CypD and induces
necrosis. A peptide Tat-p53DM
blocks the interaction of DAPK1
and p53 effectively (modified
from Pei et al., The Journal of
Neuroscience, 2014. 34(19): p.
6546–56 )
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stability by phosphorylating Pin1 (peptidylprolyl cis-trans
isomerase 1) in serine 71 [58]. In cell experiments, DAPK1
interacts and phosphorylates Tau in threonine 231, serine 231,
and serine 396. And in turn, the phosphorylated Tau can in-
hibit the death-promoting effect of DAPK1 [59]. Our recent
study provides robust evidence supporting a causative role of
Tau phosphorylation by DAPK1 in mediating dendritic spine
injuries in ischemic stroke [60]. We showed that the activated
DAPK1 phosphorylated Tau at Ser262 results in the possible
formation of indissoluble tau and accumulation in the dendrit-
ic spines, which was the possible cause of synaptic damage in
ischemic stroke. In addition, the deletion of DAPK1 kinase
domain or blocking the interaction between DAPK1 and tau
by a interfering peptide TAT-repeated 1 domain, IGSTENLK
(TAT-R1D) distinctly reduced ischemia-induced spine loss
and neuronal damage, indicating that intervening tau phos-
phorylation may be a target for the treatment of cerebral is-
chemia (Fig. 4).
DAPK1 and Caytaxin
The caytaxin gene was identified in 2003, and its mu-
tation could induce Cayman ataxia [61], which is a re-
cessive congenital disorder associated with hypotonia,
variable psychomotor retardation, cerebellar dysfunction
like truncal ataxia and intention tremor, scoliosis, and
ocular abnormalities [62]. Caytaxin is exclusively
expressed in the adult and embryonic nervous system
[63, 64]. Intriguingly, caytaxin was found to be present
in the presynaptic cytosol, suggesting its possible role
for presynaptic function [63].
Many studies reported that caytaxin plays an impor-
tant role in axonal transporting [65], glutamate synthesis
[66], synaptic apoptosis, and neurodegenerative diseases
[67]. By using coimmunoprecipitation and mass spec-
trum detection, our unpublished preliminary results
showed that DAPK1 could also interact and phosphory-
late caytaxin on serine 46 at the presynaptic area in the
mice model of middle cerebral artery occlusion
(MCAO). How this presynaptic DAPK1-caytaxin inter-
action affects synaptic transmission and neuronal fate
after ischemic stroke needs further exploration.
DAPK1 and DANGER
DANGER, a partial MAB-21 domain-containing protein,
identified on the basis of its binding to inositol 1, 4, 5-
trisphosphate receptors (IP3R) [68], binds physiological-
ly to DAPK1 [29]. Moreover, DANGER inhibits
DAPK1 activity. Loss of DANGER’s inhibition of
DAPK1 leads to enhanced cell death in the NMDA
treatment and MCAO damage in vitro and in vivo re-
spectively. Thus, drugs that enhance the inhibitory ac-
tivity of DANGER on the DAPK1 signaling pathway
might be useful in blocking cell death in stroke and
neurodegenerative diseases.
Fig. 4 Illustration for DAPK1-
Tau. DAPK1 is activated after
cerebral ischemia and
phosphorylates Tau Ser262,
inducing spine loss and the
following cell death. Blocking
DAPK1-Tau interaction with a
Tat-R1D peptide protects spine
loss and ischemic stroke damage
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Conclusion
The pathophysiology and treatment of stroke remain daunting
scientific and clinical problems. Despite impressive advances
in elucidating the complexity of cell death mechanisms, the
way forward may entail deciphering those intracellular signals
that mediate cross-talk between DAPK1 and its downstream
substrates involved in multiple pathways. Targeting DAPK1-
related pro-death signals in both presynaptic and postsynaptic
neurons may eventually lead us to improved methods to treat
salvageable brain tissues after ischemic stroke.
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